How ALS Cell Models That Began In Blood Spurred An Encouraging Early-Stage Clinical Trial

An early-stage clinical trial suggests a Parkinson's disease drug is safe and may slow symptom progression for individuals with some forms of amyotrophic lateral sclerosis (ALS) — results made possible by prior research on patient-specific motor neurons made from immune cells in the blood via a series of cellular reprogramming steps.